Online inquiry

IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5010MR)

This product GTTS-WQ5010MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets GP gene. The antibody can be applied in Ebola virus infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NP_066246.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 911829
UniProt ID Q05320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5010MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11371MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ14464MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ15407MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ3288MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ14652MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ12749MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ12371MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ2586MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 531
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW